Story

Neurocrine Biosciences Stock Declines on Vykat XR Safety Concerns and INGREZZA Pricing Risks

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20261 min read
Neurocrine Biosciences Stock Declines on Vykat XR Safety Concerns and INGREZZA Pricing Risks
Text size
Background

Shares of Neurocrine Biosciences (NBIX) declined in pre-market trading, extending a recent corrective trend as investors weigh safety signals for a newly acquired drug and unresolved pricing risks for its primary revenue driver. The stock fell 3.1% to $156.85 in pre-open trading on Wednesday, according to Investing.com.

Safety Concerns Linger for Prader-Willi Drug

The selling pressure follows a joint statement from three organizations that raised safety concerns related to Vykat XR, a treatment for Prader-Willi syndrome. The groups highlighted post-marketing safety data that included seven patient deaths and more than 100 reports of serious adverse events since the drug's approval in March 2025. An FDA database separately lists four deaths associated with the medication.

The organizations noted that these reports do not establish a direct causal relationship between the drug and the adverse outcomes. Neurocrine acquired Vykat XR, which treats the chronic, insatiable hunger known as hyperphagia, through its $2.9 billion acquisition of Soleno Therapeutics earlier this year.

Sample IUX Markets – In-articleAd

Unresolved Pricing Risks and Market Dynamics

Adding to investor uncertainty is the potential impact of Medicare's Inflation Reduction Act on Neurocrine's flagship product, INGREZZA. Management has acknowledged that the legislation could create pricing pressure between 2027 and 2029 but has not quantified the potential financial impact, leaving a key risk unresolved.

Wednesday's decline appears to be stock-specific rather than driven by broader market sentiment, suggesting investors are taking profits after a partial recovery from its 52-week low of $122.14. Despite recent price target increases from several analysts, the absence of a fresh positive catalyst has allowed these underlying concerns to weigh on the stock.

Read next

More on Stocks
Back to latest news

LATEST